José Luis Gorriz

Jun 24, 2024 | nature.com | Peter Rossing |David M. Charytan |José Luis Gorriz |Linong Ji |Roland E. Schmieder

AbstractPeople with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear.